intrathecal administration, preferably intraventricular, inhibitors of mtor in the treatment of some neurodegenerative diseases, neuro inflammatory, neuro - oncology

摘要

The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors.